We are testing a new medication for patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasms. The study aims to determine the safest dose and gather initial information on its effects.
Health conditions and diseases that the clinical trial is designed to study and treat.
Relapsed or Refractory Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow, where the disease returns after treatment or does not respond to initial therapy. It can also be associated with higher-risk types of Myelodysplastic Neoplasms, which affect blood cell production.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
